Spago Nanomedical (SPAGO) Life Science Summit 2025 summary

Company overview and technology

• Focuses on radiopharmaceutical cancer treatment using a platform technology to deliver medical ions to tumors.

• Operations are based in Sweden and Australia, with clinical development ongoing in Australia.

• Tumorad is the main clinical-stage program, aiming to treat multiple tumor types.

Industry trends and challenges

• Radioisotope-based cancer treatments are a growing field, with increased use for metastatic and hard-to-treat cancers.

• Nanomedicine enhances delivery of therapeutics to tumors, and combining it with radioisotopes is seen as a key future direction.

• The field faces challenges due to limited molecular targets and difficulties in developing stable radiopharmaceuticals.

Tumorad platform and clinical progress

• Tumorad uses nanoparticles to deliver lutetium-177 directly to tumors, independent of molecular targeting.

• The technology allows for both therapy and imaging of agent distribution in the body.

• Clinical trials in Australia have shown significant tumor uptake and an acceptable safety profile across 10 tumor types and three dose levels.

• The trial is progressing with dose escalation and aims to identify a dose for phase II studies.